Pifeltro (Doravirine)

Save 30% with Pifeltro from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Marketing Authorisation Holder and Manufacturer for Europe: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands

Prescription Pifeltro contains the active ingredient doravirine, used as a treatment for HIV. Pifeltro is classified as a NNRTI (non-nucleoside reverse transcriptase inhibitor) which blocks the activity of the enzyme that allows the HIV virus to reproduce itself.

Although Pifeltro is not a cure for HIV, it helps to keep HIV virus levels at low levels in the blood. Pifeltro is used by adults in combination with other HIV medicines to prevents further damage to the immune system and the development of diseases and infections associated with AIDS. 

Pifeltro, when used together with Truvada (emtricitabine/tenofovir) or Epzicom (abacavir/lamivudine), has shown to produce undetectable levels of the virus after 48 weeks of treatment in 83% of patients. When Pifeltro is used in combination with both Viread (tenofovir) and Epivir (lamivudine), 84% of patients after 48 weeks of treatment have undetectable levels of the HIV virus.

Pifeltro is usually taken once daily with or without food but must be taken every day even if you feel better. Take Pifeltro exactly as prescribed by your physician

Information about Pifeltro (Doravirine)

Pifeltro is an antiviral medication that contains doravirine as its active ingredient. It is used to treat HIV-1 infection in adults and children, helping to reduce the amount of HIV in the blood. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by preventing the HIV virus from replicating in the body, thus reducing the viral load and helping to manage the condition.

Product Highlights

• Pifeltro is mainly used for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older.
• It is used in combination with other antiretroviral drugs as part of a treatment regimen to suppress viral load and improve immune function in HIV-positive individuals.

Key Ingredient

• Doravirine

Key Benefits

• Pifeltro, when used as part of combination therapy, helps to lower HIV viral load and improve immune function.
• The once-daily dosage offers convenience for patients, making it easier to adhere to treatment plans.
• Doravirine is generally well-tolerated and has a lower risk of certain side effects compared to other NNRTIs.
• By controlling HIV, it helps prevent the progression to AIDS and lowers the risk of transmitting the virus to others.

Direction of Use

• Typically, Pifeltro is taken as one 100 mg tablet once a day, in combination with other antiretroviral medications, as prescribed by your healthcare provider.
• The tablet should be taken by mouth, with or without food. Swallow it whole without crushing or chewing.
• If you miss a dose, take it as soon as possible, unless it's almost time for your next dose. Do not take two doses at the same time to compensate for a missed dose.

Safety Concerns

• Some common side effects may include headache, nausea, fatigue, and dizziness.
• In rare cases, doravirine can cause serious liver problems, rash, or allergic reactions.
• Liver function should be monitored regularly, especially in patients with a history of liver disease.
• Pifeltro can interact with certain medications, including those that affect the liver enzyme CYP3A4, which may increase the risk of side effects or reduce the drug's effectiveness.
• Regular monitoring of HIV viral load and CD4 counts is important to evaluate the effectiveness of the treatment.

Avoid Pifeltro (Doravirine) If

• If you are allergic to doravirine or any other ingredients in Pifeltro, you should not use this medication.
• If you have severe liver problems, especially liver cirrhosis, you should not use Pifeltro or should use it only under close medical supervision.
• Avoid taking Pifeltro with drugs that significantly affect the CYP3A4 enzyme unless directed by a healthcare provider.
• The safety of Pifeltro during pregnancy and breastfeeding is not fully established. It is important to consult a healthcare provider to assess the risks and benefits before using this medication during these periods.